

1. **[Cardiac stent prices dropped but patients charged high : IMS Study](#) – The Economic Times**

A new IMS Study has found that the reduced prices of cardiac stents — the wire mesh used to open up clogged arteries — haven't benefited Indian patients as the overall procedure cost has spiralled over the past three years. The report, coming in the backdrop of the government's move to control prices of stents and other such medical devices, suggests prices of stents declined across private hospitals but rising drug and procedure costs kept the overall angioplasty costs high.

2. **[Pharma pricing regulator to start State-level units](#) – The Hindu Business Line**

The National Pharmaceutical Pricing Authority (NPPA) is planning to experiment by setting up units in seven states to ensure better

enforcement. The first of these State-level units would be established in Gujarat, Maharashtra, Odisha, Haryana, Kerala, Assam and Manipur at an investment of ₹4-5 lakh each. NPPA, which regulates prices of medicines and medical devices, has only one office in the national capital with no State-level units. The regulator had announced a draft central scheme to set up such Price Monitoring and Resource Units (PMRUs) in January 2015 to monitor prices of scheduled as well as non-scheduled drugs.

3. **[Pharma exporters hope for a barter-deal with African nations to beat currency blues](#) – Business Standard**

Pharma exporters from India hoping for a barter deal to be worked out with countries in Africa as well as some Latin American countries like Venezuela to help them beat currency blues. Industry sources claimed that the payments of exporters, most of whom are small and medium sized players, are stuck in the wake of liquidity issues in some of the oil exporting countries in Africa.

4. **[States' consent, draft bill set stage for GST](#) – Business Standard**

According to the draft central and integrated laws released on Tuesday, individuals and entities with an annual turnover of Rs 10 lakh or more could soon be under goods and service tax laws, widening the tax base of the government. According to the proposal of the draft laws, in the

1. [Cardiac stent prices dropped but patients charged high : IMS Study](#) – The Economic Times
2. [Pharma pricing regulator to start State-level units](#) – The Hindu Business Line
3. [Pharma exporters hope for a barter-deal with African nations to beat currency blues](#) – Business Standard
4. [States' consent, draft bill set stage for GST](#) – Business Standard
5. [New virus will not affect India's polio-free status: WHO](#) – Mint
6. [Press Release from Business Wire : Patient Safety Movement Foundation](#) – The Times of India
7. [Sun, Lupin, Aurobindo, others get show-cause notices from regulator](#) – Hindustan Times
8. [Zydus Cadila inks pact with Turkish Healthcare for biosimilars](#) – Indiainfoline.com
9. [Health groups appeal to RCEP negotiators to remove harmful IP proposals from discussions](#) – Pharmabiz.com
10. [CIPI urges health ministry to re-examine DTAB's recommendation to prohibit use of PET containers](#) – Pharmabiz.com
11. [Govt to charge fees for inspection of imported drugs, drawing of samples for test at customs](#) – Pharmabiz.com
12. [Novogen gets Australian patent covering Anisina](#) – Pharmabiz.com

northeastern states the threshold is even lower at Rs 5 lakh. The draft laws also propose collection of taxes at source for e-commerce companies, including aggregators, and simplify the definition of “services” to include intangibles such as software and work contracts.

5. [New virus will not affect India’s polio-free status: WHO](#) – Mint

The World Health Organization (WHO) on Wednesday said the detection of vaccine-derived polio virus (VDPV) in different parts of the country does not change India’s polio-free status, and described it as a “low-level threat”. VDPV is a rare strain of the polio virus that is the result of a mutation of the one contained in the oral polio vaccine (OPV).

6. [Press Release from Business Wire : Patient Safety Movement Foundation](#) – The Times of India

The Patient Safety Movement Foundation announced three new patient safety challenges at its Midyear Planning Meeting co-convened with Inova. The 2016 Midyear Planning Meeting brought together over 100 medical experts, administrators, patient advocates and government officials from around the world for presentations and discussions on critical topics in patient safety. The meeting concluded with a discussion and vote to select the new challenges where patient death can be easily prevented if proper protocols are followed during patient care. Attendees nominated 15 new challenges.

7. [Sun, Lupin, Aurobindo, others get show-cause notices from regulator](#) – Hindustan Times

The National Pharmaceutical Pricing Authority (NPPA) has slapped show-cause notices on 10 top drugmakers, including Sun Pharma, Lupin and Aurobindo Pharma, for not submitting relevant information about the names of formulations manufactured and marketed by them. Besides these companies, notices have also been sent to a few other smaller firms. Sun Pharma and Lupin are India’s top two pharma companies by market value.

8. [Zydus Cadila inks pact with Turkish Healthcare for biosimilars](#) – Indiainfoline.com

Zydus Cadila and Eczac1ba1ilac; a leading healthcare company of Turkey have signed a strategic collaboration agreement to market biotech products in the Turkish market. The agreement involves the import of biosimilars which are currently unavailable in the country especially for the treatment of cancer and also paves the way for a long term strategic collaboration to produce and launch new products in the market.

9. [Health groups appeal to RCEP negotiators to remove harmful IP proposals from discussions](#) – Pharmabiz.com

The 13th round of negotiations of the Regional Comprehensive Economic Partnership (RCEP) trade deal, Médecins Sans Frontières (MSF) and other health organisations have appealed for the removal of alarming intellectual property proposals tabled by Japan and South Korea that will go beyond what international trade rules require, and would undermine access to affordable generic medicines. A leaked copy of the intellectual property text being discussed at the negotiations shows that Japan and South Korea have made several alarming proposals to include intellectual property rules that go beyond what international trade rules require, and that would undermine access to affordable generic medicines.

10. [CIPI urges health ministry to re-examine DTAB's recommendation to prohibit use of PET containers](#) – Pharmabiz.com

Irked over the Drugs Technical Advisory Board (DTAB)'s recommendation to prohibit the use of PET containers for packing of liquid oral formulations, Confederation of Indian Pharmaceutical Industry (CIPI) has urged the Union health ministry to re-examine existing specifications and standards of PET containers in line with the international standards and revise them if needed, rather than banning it. CIPI, an apex body of the small and medium drug manufacturers, recently submitted a memorandum to the Union ministry in this regard.

11. [Govt to charge fees for inspection of imported drugs, drawing of samples for test at customs](#) – Pharmabiz.com

The Union health ministry will soon charge fees for inspection of the imported consignments and drawing of samples of drugs including medical devices for test analysis at customs under

the provisions of Drugs & Cosmetics Rules. A proposal of the ministry in this regard has found favour with the Drugs Technical Advisory Board (DTAB), which is the highest authority under the Union health ministry on technical matters. The issue came up before the DTAB for its consideration of the proposal at its 71st meeting held on May 13, 2016. After detailed deliberations, the DTAB agreed in principle for charging of fees for examination of the consignments. However, the quantum of the fee may be decided in consultation with the stakeholders by the government.

12. [Novogen gets Australian patent covering Anisina](#) – Pharmabiz.com

The Australian- US drug development company, Novogen Ltd announced that a patent for the ATM-3500 series had been granted in Australia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507). Novogen North America CEO, Dr Andrew Heaton, commented: "This patent provides full protection for Anisina in Australia through to 2035. Together with the SBP patent that was granted in February, today's news means that all three of Novogen's development candidates -- Cantrixil, Anisina and Trilexium -- are fully covered in Australia. With our strategy of utilizing the extensive global patent superhighway convention we anticipate a very smooth roll out of these patents globally."